22nd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy
October 1-4, 2020

Chairs: J. Cortes, T.P. Hughes, D.S. Krause


Thursday, October 1, 2020

14:00-14:10 WELCOME Jorge Cortes (Augusta)
14:10-14:20 iCMLf - A REVIEW Tim P. Hughes (Adélaide)
14:20-14:53 SPECIAL INTRODUCTORY LECTURE
Chair: Jerry Radich (Seattle)

14:20-14:23 Introduction

14:23-14:43 Finding relapse-fated cells at diagnosis and targeting relapse before it evolves John Dick (Toronto)

14:43-14:53 Discussion

14:53-16:40 SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2020
Chairs: Brian Huntly (Cambridge), Francois-Xavier Mahon (Bordeaux)

14:53-14:56 Introduction

14:56-15:08 Targeted RNA-Based Gene Sequencing Identifies Mutated Blood Cancer-Linked Genes at Diagnosis of CML That Are Associated with Treatment Failure Susan Branford (Adelaide)

15:08-15:20 Tgfβr - SMAD3 Signaling Protects CML and Other Myeloid Malignancies from Synthetic Lethality Triggered By PARP Inhibitor in Bone Marrow Microenvironment Bac Viet Le (Warsaw/Philadelphia)

15:20-15:32 Interim Analysis from the Optic Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib Jorge Cortes (Augusta)

15:32-15:44 Deceiving and Drugging BCR-ABL1 Compound Mutants: Pairing a Conformational Influencer with Asciminib or an Asciminib Proteolysis-Targeting Chimera (PROTAC) Thomas O’Hare (Salt Lake City)
Therapeutic Inhibition of Malignant Fcγrllb-Induced BTK Activation Targets Leukemic Stem Cells in Chronic Myeloid Leukemia  
Mirle Schemionek (Aachen)

Molecular Status 36 Months after TKI-Discontinuation in CML Is Highly Predictive for Later Loss of MMR - a Report from after-SKI.  
Johan Richter (Lund)

Protein Transfer between CML and Bone Marrow Stromal Cells: Functional Meaning and the Involvement of Tnts  
Marta Kolba (Warsaw)

Discussion

Break

TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE
Chair: Steffen Koschmieder (Aachen)

Introduction

Understanding and targeting the stem cell origins of myeloid malignancies  
Ulrich Steidl (New York)

Discussion

SCIENTIFIC SESSION 2: STEM CELLS AND THE MICROENVIRONMENT
Chairs: Daniela Krause (Frankfurt) and Ram Thakur (Lund)

Introduction

Regulation of hematopoietic stem and progenitor cells by the bone marrow microenvironment  
Ralf Adams (Munster)

Discussion

Selected Abstracts

The Role of the Autophagy Adaptor Protein PLEKHM1 in the Leukaemic Bone Marrow Microenvironment  
Christina Karantanou (Frankfurt)

Features of BCR-ABL1 Driven Myeloproliferative Disease in a CML Mouse Model Are Dependent on LSC Age and Fitness  
Hassan Almasoudi (Glasgow)

Murine Hematopoietic and Leukemic Stem/Progenitor Cell Lines As Model Systems for Bcr/Abl Driven Disease  
Veronika Sexl (Vienna)

Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Drug-Resistant CML Stem/Progenitor Cells  
Andrew Wu (Vancouver)

The Spliceosome: An Another Regulating System of Gene Expression Deregulated in CP-CML CD34+CD15- Cells  
Benjamin Lebecque (Clermont-Ferrand)

Discussion
**JANET ROWLEY PRIZE PRESENTATION**
**Presenter:** Rob Welner (Birmingham)
**Awardee 2020:** Ravi Bhatia (Birmingham)

**JANET ROWLEY PRIZE: SPECIAL LECTURE (2)**
**Chair:** Rob Welner (Birmingham)

The seed and the soil – the leukemia stem cell in its niche and the quest for cure

Ravi Bhatia (Birmingham)

**Discussion**

---

**Friday, October 2, 2020**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30-12:15</td>
<td><strong>SCIENTIFIC SESSION 3: IMMUNOLOGY AND INFLAMMATION</strong></td>
<td>Shinya Kimura (Saga)</td>
</tr>
<tr>
<td>11:30-11:33</td>
<td><em>Introduction</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Selected Abstracts</em></td>
<td></td>
</tr>
<tr>
<td>11:33-11:45</td>
<td>Sterile Inflammation in Normal Hematopoiesis and Leukemia</td>
<td>Pablo Llavona (Frankfurt)</td>
</tr>
<tr>
<td>11:45-11:57</td>
<td>Immunosuppressive Polarization of T Cell Subsets in Spleen and Bone Marrow of Mice with CML-like Disease</td>
<td>Julian Swatler (Warsaw)</td>
</tr>
<tr>
<td>11:57-12:15</td>
<td><em>Discussion</em></td>
<td></td>
</tr>
<tr>
<td>12:15-14:00</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>

**SATELLITE SYMPOSIUM:**
**RECENT HIGHLIGHTS IN CML: WHAT HAVE WE LEARNED IN 2020?**
**Chair:** Philippe Rousselot (France)
**Speakers:** Mario Tiribelli (Italy), Jorge Cortes (USA)

*This educational symposium is organized and funded by Incyte Biosciences International Sàrl*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-15:33</td>
<td><strong>SCIENTIFIC SESSION 4: THE BIOLOGY OF BLAST PHASE</strong></td>
<td>Adam Mead (Oxford)*</td>
</tr>
<tr>
<td>14:00-14:03</td>
<td><em>Introduction</em></td>
<td></td>
</tr>
<tr>
<td>14:03-14:18</td>
<td><em>Keynote Presentation</em></td>
<td>Daniel Bolon (Amherst)</td>
</tr>
<tr>
<td></td>
<td>CRISPR predictions about relapse in CML</td>
<td></td>
</tr>
<tr>
<td>14:18-14:28</td>
<td><em>Discussion</em></td>
<td></td>
</tr>
</tbody>
</table>
### Selected Abstracts

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:28-14:40</td>
<td>RUNX1 Mutations in Blast Phase Chronic Myeloid Leukemia</td>
<td>Shady Adnan-Awad (Helsinki)</td>
</tr>
<tr>
<td>14:40-14:52</td>
<td>H3K36ME3 Loss in Chronic Myeloid Leukemia Patients in Blast Crisis Is Mediated by an Unbalanced SETD2/KDM4A Activity and CAN be Therapeutically Targeted</td>
<td>Manuela Mancini (Bologna)</td>
</tr>
<tr>
<td>14:52-15:04</td>
<td>Releasing the Brakes on Apoptosis: Investigating Combinations of BH3 Mimetics and Nilotinib in Blast Phase CML</td>
<td>Narissa Parry (Glasgow)</td>
</tr>
<tr>
<td>15:04-15:16</td>
<td>Discovery of Novel CIP2A Variant (NOCIVA) and its Clinical Association with Myeloid Leukemias</td>
<td>Eleonora Mäkelä (Turku)</td>
</tr>
<tr>
<td>15:16-15:33</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**15:35**

**Biology Posters - Mentored Poster Walk 1**

**Biology Poster Walk Leaders:** Sin Tiong Ong (Singapore), Stéphane Prost (Fontenay-aux-Roses)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:35 – 16:35</td>
<td><strong>CONCURRENT MEET-THE-EXPERT SESSIONS</strong> (pre-registration required)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical trial design</td>
<td>Donald Berry (Houston) and Joëlle Guilhot (Poitiers)</td>
</tr>
<tr>
<td></td>
<td>New drugs under development</td>
<td>Jorge Cortes (Augusta) and Tim Hughes (Adelaide)</td>
</tr>
<tr>
<td></td>
<td>Understanding and analyzing the new ELN recommendations</td>
<td>Andreas Hochhaus (Jena) and Michael Mauro (New York)</td>
</tr>
<tr>
<td>16:35-16:45</td>
<td><strong>Convene in the Main Conference Hall</strong></td>
<td></td>
</tr>
</tbody>
</table>

**16:45 -18:20**

**SPECIAL SYMPOSIUM ON ONCOIMMUNOLOGY IN HEMATOLOGIC MALIGNANCIES**

**Chairs:** Jorge Cortes (Augusta), Kimmo Porkka (Helsinki)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:45-16:55</td>
<td>Introductory overview – concepts and challenges</td>
<td></td>
</tr>
<tr>
<td>16:55-17:07</td>
<td>Leukemia vaccines</td>
<td>David Scheinberg (New York)</td>
</tr>
<tr>
<td>17:07-17:19</td>
<td>CAR-T for myeloid malignancies</td>
<td>Saar Gill (Philadelphia)</td>
</tr>
<tr>
<td>17:19-17:31</td>
<td>Bi-specific and allogeneic CAR-T</td>
<td>Xianxin Hua (Philadelphia)</td>
</tr>
<tr>
<td>17:31-17:43</td>
<td>Checkpoint inhibitors</td>
<td>Justin Kline (Chicago)</td>
</tr>
<tr>
<td>17:43-17:55</td>
<td>Bispecific antibodies in myeloid leukemias</td>
<td>Roland Walter (Seattle)</td>
</tr>
<tr>
<td>17:55-18:20</td>
<td>General Discussion</td>
<td></td>
</tr>
</tbody>
</table>
18:20-18:53  SPECIAL LECTURE (3):
Chair: Rick Van Etten (Irvine)

Introduction

18:23-18:43  CML blast crisis and the microenvironment  Tannishtha Reya (San Diego)

18:43-18:53  Discussion

18:55 – 19:55  CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)

Hematopoiesis  Timm Schroeder (Basel)

Immunological approaches to the treatment of leukemia  Roland Walter (Seattle) and David Scheinberg (New York)

Saturday, October 3, 2020

08:50-10:50  WORKSHOP FOR NON-CLINICAL SCIENTISTS #1
PROTEOMICS / SECRETOMICS
Chairs: Oliver Hantschel (Marburg) and Vignir Helgason (Glasgow)

08:50-08:55  Introduction  Oliver Hantschel (Marburg) and Vignir Helgason (Glasgow)

08:55-09:20  An integrated platform for biomarker and drug target discovery using proteomics  Anthony Whetton (Manchester)

09:20-09:45  MS-proteomics to uncover the complexity and function of the cell secretome  Sara Zanivan (Glasgow)

09:45-10:10  Title: TBA  Oliver Schilling (Freiburg)

10:10-10:40  Discussion

10:40-10:50  Conclusion

11:00-11:10  JOHN GOLDMAN PRIZE PRESENTATION
Presenter: Hemant Malhotra (Jaipur)
Awardee 2020: Jane Apperley (London)

11:10-11:30  JOHN GOLDMAN PRIZE: SPECIAL LECTURE (4)
Chair: Hemant Malhotra (Jaipur)
CML and me: reflections on the roadmap to cure  Jane Apperley (London)

11:30-11:40  Discussion
11:40-13:10  SCIENTIFIC SESSION 5: NEW TREATMENT STRATEGIES
Chair: Gianantonio Rosti (Bologna)

11:40-11:43  Introduction

11:43-11:58  Keynote Presentation  Andreas Hochhaus (Jena)

11:58-12:08  Discussion

Selected Abstracts

12:08-12:20  A Novel Oral Demethylating Agent, or-2100, in Combination with Tyrosine Kinase Inhibitors Overcomes Resistance in Chronic Myeloid Leukemia  Kazuharu Kamachi (Saga)

12:20-12:32  Targeting Integrated Stress Response Combined with Imatinib As a Novel Strategy to Eradicate Imatinib-Resistant CML Cells  Katarzyna Piwocka (Warsaw)

12:32-12:44  Activity of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) in CML Patients Failing TKI Therapies Including Ponatinib  Jorge Cortes (Augusta)

12:44-12:56  Radotinib Treatment for Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to or Intolerant of BCR-ABL1 Tyrosine-Kinase Inhibitors: 60-Month Follow-up of a Phase 2 Study  Sung-Hyun Kim (Busan)

12:56-13:10  Discussion

13:10-14:50  Lunch

13:20-14:50  SATELLITE SYMPOSIUM:
TRAVELING THROUGH THE UNSOLVED NEEDS IN CML: TOWARDS NEW STRATEGIES
Chair: Andreas Hochhaus (Jena)
Speakers: Valentin Garcia-Gutiérrez (Madrid), Massimo Breccia (Roma), Delphine Réa (Paris)

This educational symposium is organized and funded by Novartis Oncology

14:50-15:00  Convene in the Main Conference Hall

15:00-15:10  ESH INTERNATIONAL JOHN GOLDMAN RESEARCH AWARD CEREMONY
Presenter:

Awardee 2020: Vaidehi Krishnan (Singapore)
High dimensional single-cell analysis to predict TFR at the time of CML diagnosis
15:20-16:55  SCIENTIFIC SESSION 6: TREATMENT-FREE REMISSION  
Chair: Dragana Milojkovic (London)*  

15:20-15:23  Introduction  

15:23-15:38  Keynote Presentation  
Susanne Saussele (Mannheim)  

15:38-15:48  Discussion  

Selected Abstracts  

15:48-16:00  The rate of BCR-ABL1 decline after TKI commencement is a strong predictor of sustained Treatment Free Remission  
Naranie Shanmuganathan (Adelaide)  

16:00-16:12  High Level of Successful TKI Discontinuation Outside Clinical Trials - a Population-Based Study from the Swedish CML Registry  
Johan Richter (Lund)  

16:12-16:24  Efficacy and Safety of Pioglitazone in a Phase II Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia Patients  
Katia Pagnano (Campinas)  

16:24-16:36  Update of the French Spirit Trial with a Detailed Focus on Treatment Free Remission  
François Guilhot (Poitiers)  

16:36-16:55  Discussion  

16:55-17:05  Break  

17:05-18:50  SCIENTIFIC SESSION 7: TREATMENT-FREE REMISSION - PREDICTIVE FACTORS  
Chair: Delphine Rea (Paris)  

17:05-17:08  Introduction  

17:08-17:23  Keynote Presentation  
Agnes Yong (Adelaide)  

17:23-17:33  Discussion  

Selected Abstracts  

17:33-17:45  BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Early Predictive Surrogate for Treatment-Free Remission Failure after Imatinib Discontinuation  
Dennis Kim (Toronto)  

17:45-17:57  Chronic Myeloid Leukemia Patients’ Concerns during Phase I of the Treatment-Free Remission Journey: Considerations Between Patients and Doctors in the Different CML Advocates Network Regions  
Giora Sharf (Netanya)  

17:57-18:09  Best Duration of Deep Molecular Remission to Achieve Therapy-Free Remission in Chronic Myeloid Leukaemia  
Robert Gale (London)
18:09-18:21  Risk Factor Analysis for Treatment-Free Remission Failure after Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia in Chronic Phase: The Optimal Duration of Total Imatinib Treatment and MR4 Response  
  
Dennis Kim (Toronto)

18:21-18:33  Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study  
  
Frédéric Millot (Poitiers)

18:33-18:50  Discussion

18:50-19:23  SPECIAL LECTURE (5):  
  Chair: Giovanni Martinelli (Meldola)

18:50-18:53  Introduction

18:53-19:13  Human evolutionary genomic medicine  
  Melissa Ilardo (Salt Lake City)

19:13-19:23  Discussion

Sunday, October 4, 2020

14:30-16:30  WORKSHOP FOR NON-CLINICAL SCIENTISTS #2  
ARTIFICIAL INTELLIGENCE / MACHINE LEARNING  
  Chairs: Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)

14:30-14:35  Introduction  
  Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)

14:35-15:00  Long-term single-cell quantification: new tools for old questions  
  Timm Schroeder (Basel)

15:00-15:25  Computational Pathology: Towards Precision Medicine  
  Andrew Janowczyk (Cleveland)

15:25-15:50  TBA  
  Jeffrey Humpherys (Salt Lake City)

15:50-16:20  Discussion

16:20-16:30  Conclusion

15:30-16:30  Clinical Posters - Mentored Poster Walk 2

  Clinical Poster Walk Leaders: Franck Nicolini (Lyon), Pierre Laneuville (Montreal)

16:30-17:03  SPECIAL LECTURE (6):  
  Chair: Catriona Jamieson (La Jolla)

16:30-16:33  Introduction

16:33-16:53  Single cell RNA sequencing in MPN  
  Bethan Psaila (Oxford)

16:53-17:03  Discussion
17:03-18:20  DEBATE: “SWITCH TO A MORE POTENT DRUG TO GAIN ELIGIBILITY FOR TFR?”
Chair: Bengt Simonsson (Uppsala)*

17:03-17:06  Introduction

17:06-17:10  Voting

17:10-17:30  Against: Charles Schiffer (Detroit)

17:30-17:50  For: Giuseppe Saglio (Turin)

17:50-18:20  Voting and Discussion

18:20-18:30  iCMLf PRIZE PRESENTATION:
Presenter: Jerry Radich (Seattle)
Awardee 2020: Sabira Kurtovic (Sarajevo)

18:30-18:50  iCMLf PRIZE: SPECIAL LECTURE (7)
Chair: Jerry Radich (Seattle)

CML management in war and peace: lessons that shaped future approaches
Sabira Kurtovic (Sarajevo)

18:50-19:00  Discussion

19:00-20:20  SCIENTIFIC SESSION 8: TKI SAFETY
Chair: Javier Pinilla-Ibarz (Tampa)

19:00-19:03  Introduction

19:03-19:18  Keynote presentation
Novel trial designs
Donald Berry (Houston)

19:18-19:28  Discussion

Selected Abstracts

19:28-19:40  Cellular Metabolic Flexibility to Explain Interindividual Susceptibility for Tyrosine Kinase Inhibitor-Induced Muscle Complaints
Lando Janssen (Nijmegen)

19:40-19:52  Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia
James Januzzi (Boston)

19:52-20:04  High Body Mass Index (BMI) and Treatment Responses in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Receiving First-Line Dasatinib or Imatinib: Exploratory Post Hoc Analysis of the Phase 3 DASISION Study
Massimo Breccia (Rome)

20:04-20:20  Discussion

20:20  Meeting Adjourned  * pending confirmation